Compounds > piracetam
Page last updated: 2024-08-16

piracetam and busulfan

piracetam has been researched along with busulfan in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's5 (83.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Anderson, GD; Bubalo, JS; Eberly, AL; McCune, JS1
Bajwa, RP; Gross, TG; Pai, V; Skeens, M; Soni, S; Termuhlen, AM1
Azık, F; Tavil, B; Teber, S; Tunç, B; Uçkan, D; Yazal Erdem, A1
Floeter, AE; McCune, JS1

Reviews

1 review(s) available for piracetam and busulfan

ArticleYear
Optimal prevention of seizures induced by high-dose busulfan.
    Pharmacotherapy, 2008, Volume: 28, Issue:12

    Topics: Alkylating Agents; Animals; Anticonvulsants; Benzodiazepines; Busulfan; Dose-Response Relationship, Drug; Humans; Levetiracetam; Piracetam; Seizures

2008

Other Studies

5 other study(ies) available for piracetam and busulfan

ArticleYear
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Levetiracetam for busulfan-induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation.
    Pediatric blood & cancer, 2012, Volume: 59, Issue:4

    Topics: Adolescent; Adult; Anticonvulsants; Busulfan; Child; Child, Preschool; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Levetiracetam; Phenytoin; Piracetam; Seizures; Transplantation Conditioning; Young Adult

2012
Busulfan triggers epileptic seizures under levetiracetam and valproic acid therapy.
    Pediatric transplantation, 2014, Volume: 18, Issue:4

    Topics: Adolescent; Anticonvulsants; Busulfan; Drug Therapy, Combination; Epilepsy; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Levetiracetam; Piracetam; Transplantation Conditioning; Valproic Acid

2014
Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2017, Volume: 23, Issue:5

    Topics: Adolescent; Anticonvulsants; Busulfan; Child; Child, Preschool; Female; Graft Rejection; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Infant; Levetiracetam; Male; Myeloablative Agonists; Phenytoin; Piracetam; Recurrence; Retrospective Studies; Seizures; Transplantation Conditioning; Young Adult

2017